PTC Therapeutics layoffs, on the record
Every job cut, severance charge and restructuring PTC Therapeutics reported in its annual reports, 2023 to 2025, quoted from the filings.
Job cuts, severance and restructuring
Our summaryReduced the workforce as part of a strategic pipeline prioritization, mainly affecting US employees in early-stage research, gene therapy manufacturing, and related selling, general and administrative roles.
Word for word“In connection with the strategic pipeline prioritizations, we reduced our workforce by 32%, which primarily affected employees in the United States, including those employees involved in early-stage research and gene therapy manufacturing and associated selling, general and administrative functions.” 10-K for 2023
Our summarySubstantially completed the workforce reduction.
Word for word“We substantially completed the reduction in workforce in January 2024.” 10-K for 2023
Our summaryIncurred restructuring costs from the workforce reduction and the discontinuation of preclinical and early research programs in the gene therapy platform.
Word for word“During the year ended December 31, 2023, the Company incurred $ 32.8 million of restructuring costs from a reduction in workforce in connection with the Company’s strategic pipeline prioritization and discontinuation of its preclinical and early research programs in its gene therapy platform.” 10-K for 2023
Our summaryThe company reduced its workforce in 2023 as part of its strategic pipeline prioritization and discontinued preclinical and early research programs in its gene therapy platform, with restructuring costs recorded in 2023.
Word for word“The increase also includes restructuring costs from a reduction in workforce in connection with our strategic pipeline prioritization and discontinuation of our preclinical and early research programs in our gene therapy platform in the year ended December 31, 2023.” 10-K for 2024
Our summaryAccrued restructuring costs from the 2023 workforce reduction were included within employee compensation, benefits, and related accruals, declining from prior year.
Word for word“As of December 31, 2024 and December 31, 2023, there were $ 0.1 million and $ 9.0 million, respectively, of accrued restructuring costs included above within employee compensation, benefits, and related accruals from a reduction in 174 Table of Contents PTC Therapeutics, Inc.” 10-K for 2024
Our summaryThe company reduced its workforce in 2023 as part of a strategic pipeline prioritization, and later discontinued preclinical and early research programs in its gene therapy platform, which changed payroll, benefits and share-based compensation expenses.
Word for word“For the year ended December 31, 2025, compared to the years ended December 31, 2024 and 2023, the change in payroll, benefits, and share-based stock compensation expenses primarily relates to our reduction in workforce in connection with our strategic pipeline prioritization in 2023 and discontinuation of our preclinical and early research programs in our gene therapy platform.” 10-K for 2025
Our summarySelling, general and administrative expense fell in 2024 compared with 2023, which the company attributes to lower employee costs after the 2023 workforce reduction.
Word for word“The decrease reflected lower employee costs as a result of the reduction in workforce in 2023.” 10-K for 2025
| Fiscal year ended | Restructuring charges | Cash paid for restructuring |
|---|---|---|
| 2017-12-31 | $0 | $22,000 |
PTC Therapeutics filed 3 restructuring notices (Form 8-K, Item 2.05) since 2016. This page shows what the company reported to the SEC, not news reports or state layoff notices.
Read from PTC Therapeutics’s annual reports (10-K for 2025, 10-K for 2024, 10-K for 2023) and the financial data it files with the SEC, as of 2026-02-19. Every quotation is word for word from the filing linked beside it; how these pages are built and checked. The full record is in its company data sheet.